Product Description
Ganciclovir capsules are used to treat cytomegalovirus (CMV) retinitis (eye infection that can cause blindness) in people whose immune system is not working normally. Ganciclovir capsules are used to treat CMV retinitis after the condition has been controlled by intravenous (injected into a vein) ganciclovir. Ganciclovir is also used to prevent cytomegalovirus (CMV) disease in people who have acquired immunodeficiency syndrome (AIDS) or who have received an organ transplant and are at risk of CMV disease. Ganciclovir is in a class of medications called antivirals. It works by preventing the spread of CMV disease or slowing the growth of CMV. (Sourced from: https://medlineplus.gov/druginfo/meds/a605011.html)
Mechanisms of Action: DNA Polymerase Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous, Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Czech | Denmark | Dominican Republic | Ecuador | Egypt | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Hoffmann-La Roche
Company Location:
Company CEO: Severin Schwan
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, China, Japan, Spain
Active Clinical Trial Count: 6
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Liver Cancer|Liver Transplant|Renal Transplant
Phase 2: Deficiency Diseases|Herpes Simplex|Keratitis
Phase 1: Autism Spectrum Disorder
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ACTRN12620000234910p |
2006-7041-83/hah | P1 |
Not yet recruiting |
Autism Spectrum Disorder |
2020-06-16 |
|||
NCT06474442 |
BD-HSK-111002-â ¡a | P2 |
Recruiting |
Keratitis|Herpes Simplex |
2026-12-01 |
12% |
2025-05-20 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
2025-520742-29-00 |
FCO-INM-2024-01 | P3 |
Not yet recruiting |
Renal Transplant |
2029-09-08 |
|||
CTR20192005 |
CTR20192005 | P2 |
Recruiting |
Deficiency Diseases |
None |
2025-04-29 |
Patient Enrollment|Treatments|Trial Status |
|
jRCT2051210064 |
jRCT2051210064 | P3 |
Active, not recruiting |
Unknown |
2022-12-31 |
|||
CTR20132308 |
CTR20132308 | P3 |
Recruiting |
Liver Transplant|Liver Cancer |
None |
2025-04-29 |
Patient Enrollment|Treatments |